

Supply Disruption Alert

SDA/2020/007

Issued: 07 May 2020

Valid until: 30/10/2020

Phosphate Polyfusor® 500ml – Supply Disruption

Summary

- Phosphate Polyfusors® will be out of stock until at least October 2020.
- Sodium glycerophosphate 21.6% injection (Glycophos®) remains available.
- Addiphos® also remains available, however, as it contains a high concentration of potassium its use must be in compliance with local potassium policies.

Action

Trust pharmacy procurement teams should ensure the following actions are undertaken:

- i. assess local stock holding of Phosphate Polyfusors®;
- ii. consider centralising stock at pharmacy;
- iii. work with clinical colleagues and the local Medicines Safety Officer (MSO) to:
 - agree priority indications for which remaining Phosphate Polyfusors® will be reserved;
 - consider using sodium glycerophosphate 21.6% injection (Glycophos®) for phosphate replacement (see further information below);
 - consider using Addiphos® where appropriate (see further information below).

Deadlines for actions

Actions underway: 11/05/2020

Actions completed: 30/10/2020

Product details

Phosphate Polyfusor® 500ml

Problem / background

There is a supply issue affecting Phosphate Polyfusors® due to a change in adhesive by the label supplier which requires further in-house regulatory validation. Fresenius Kabi are the sole licensed UK supplier of Phosphate Polyfusors®.

It is anticipated that current stock will be depleted in early May 2020. Further supplies are not anticipated before October 2020, however exact resupply dates are not confirmed.

Alternative products and administration advice

Phosphate polyfusors® contain **50mmol phosphate** and **81mmol sodium in 500ml** and are usually given over 6-12 hours.

Each Glycophos® vial contains **20mmol phosphate** and **40mmol sodium in 20ml** and must be diluted prior to use.

Examples of dilutions for peripheral administration:

- In order to administer 20mmol of phosphate, dilute 20mL of Glycophos® in 250mL glucose 5% or sodium chloride 0.9%
- In order to administer 50mmol of phosphate, dilute 50mL of Glycophos® in 500mL glucose 5% or sodium chloride 0.9%

Once diluted, it can be administered via an infusion pump over at least 8 hours (or follow local protocols).

NB: Concentrated solutions (e.g. 20mmol in 50mL) must be given **via a central venous access device** due to high osmolality.

Please refer to the Glycophos® monograph on Medusa (link below and shared with this alert) and local Trust guidance on phosphate replacement for further information.

<http://www.injmed.nhs.uk/IVGuideVTMSelect.asp?VTM=415542004&ID=a09bf37d72e3f1f763de8d5ea56a40bc4134>

Addiphos® (20mL ampoule) is a strong potassium solution that contains 40 mmol phosphate, 30 mmol potassium and 30 mmol sodium. Its use as intravenous phosphate supplementation must be risk assessed locally and be in compliance with local potassium policies.

Distribution

Trusts (NHS boards in Scotland)

CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:

- | | |
|--|---|
| • A&E consultants | • Intensive care nursing staff (paediatric) |
| • A&E departments | • Intensive care units |
| • A&E directors | • Intensive care, directors of |
| • A&E nurses | • Medical directors |
| • Adult intensive care units | • Paediatric intensive care units |
| • Chief pharmacists | • Paediatric medicine, directors of |
| • Clinical governance leads | • Paediatric nurse specialists |
| • Clinical Procurement Specialists | • Paediatric wards |
| • Hospital pharmacies | • Paediatricians |
| • Hospital pharmacists | • Paediatrics departments |
| • Intensive care medical staff/paediatrics | • Pharmaceutical advisors |
| • Intensive care nursing staff (adult) | • Pharmacists |

Independent distribution

Establishments registered with the Care Quality Commission (CQC) (England only)

- Hospitals in the independent sector

Enquiries

England

Enquiries from NHS Trusts in England should in the first instance be directed to your trust pharmacy team who will escalate issues to the Regional Pharmacy Procurement Specialist and national teams if required.

REGION	Full Name	Email
East Midlands	Andi Swain	andi.swain@nhs.net
East of England	James Kent	james.kent@southend.nhs.uk
London	Jackie Eastwood	jacqueline.eastwood@lpp.nhs.uk
North East	David Cook	David.Cook@nth.nhs.uk
North West	Glenn Harley	Glenn.Harley@liverpoolft.nhs.uk
South Central	Alison Ashman	Alison.Ashman@berkshire.nhs.uk
South East Coast	Richard Bateman	richard.bateman2@nhs.net
South West	Danny Palmer	Danny.Palmer@UHBristol.nhs.uk
West Midlands	Diptyka Hart	Diptyka.Hart@uhb.nhs.uk
Yorkshire & Humber	David Allwood	davidallwood@nhs.net

Scotland

NSS.NHSSMedicineShortages@nhs.net

Wales

MedicinesShortages@gov.wales

Northern Ireland

Noel.dunn@northerntrust.hscni.net

Send enquiries about this notice to the DHSC Supply Resilience Team, quoting reference number SDA/2020/007

Email: supplyresiliencemd@dhsc.gov.uk